Whitney Ijem
Stock Analyst at Canaccord Genuity
(3.13)
# 1,096
Out of 4,829 analysts
99
Total ratings
39.76%
Success rate
2.23%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Whitney Ijem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RGLS Regulus Therapeutics | Downgrades: Hold | $28 → $11 | $7.87 | +39.77% | 6 | Apr 30, 2025 | |
| VERV Verve Therapeutics | Maintains: Buy | $32 → $39 | $4.23 | +821.99% | 5 | Apr 15, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $81 → $92 | $57.38 | +60.33% | 7 | Apr 8, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $385 → $390 | $251.15 | +55.29% | 8 | Mar 21, 2025 | |
| GBIO Generation Bio Co. | Maintains: Buy | $9 | $0.36 | +2,400.00% | 2 | Mar 17, 2025 | |
| TNYA Tenaya Therapeutics | Maintains: Buy | $18 → $6 | $0.41 | +1,349.63% | 6 | Mar 13, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Buy | $74 → $68 | $10.98 | +519.31% | 5 | Mar 10, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $39 → $36 | $6.99 | +415.02% | 6 | Mar 3, 2025 | |
| PVLA Palvella Therapeutics | Maintains: Buy | $39 | $22.77 | +71.28% | 2 | Feb 26, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $121 → $136 | $35.11 | +287.35% | 8 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Hold | $408 → $424 | $424.99 | -0.23% | 8 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 | $8.12 | +1,008.37% | 5 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $8 | $2.13 | +275.59% | 8 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 | $0.33 | +3,848.97% | 6 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $148 → $150 | $36.27 | +313.56% | 3 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $93 → $84 | $58.86 | +42.71% | 8 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $96.91 | - | 2 | Jan 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $120 → $240 | $6.02 | +3,890.02% | 4 | Jul 23, 2019 |
Regulus Therapeutics
Apr 30, 2025
Downgrades: Hold
Price Target: $28 → $11
Current: $7.87
Upside: +39.77%
Verve Therapeutics
Apr 15, 2025
Maintains: Buy
Price Target: $32 → $39
Current: $4.23
Upside: +821.99%
Rhythm Pharmaceuticals
Apr 8, 2025
Maintains: Buy
Price Target: $81 → $92
Current: $57.38
Upside: +60.33%
Alnylam Pharmaceuticals
Mar 21, 2025
Maintains: Buy
Price Target: $385 → $390
Current: $251.15
Upside: +55.29%
Generation Bio Co.
Mar 17, 2025
Maintains: Buy
Price Target: $9
Current: $0.36
Upside: +2,400.00%
Tenaya Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $18 → $6
Current: $0.41
Upside: +1,349.63%
Arcturus Therapeutics Holdings
Mar 10, 2025
Maintains: Buy
Price Target: $74 → $68
Current: $10.98
Upside: +519.31%
Rocket Pharmaceuticals
Mar 3, 2025
Maintains: Buy
Price Target: $39 → $36
Current: $6.99
Upside: +415.02%
Palvella Therapeutics
Feb 26, 2025
Maintains: Buy
Price Target: $39
Current: $22.77
Upside: +71.28%
Ultragenyx Pharmaceutical
Feb 18, 2025
Maintains: Buy
Price Target: $121 → $136
Current: $35.11
Upside: +287.35%
Feb 12, 2025
Upgrades: Hold
Price Target: $408 → $424
Current: $424.99
Upside: -0.23%
Nov 19, 2024
Maintains: Buy
Price Target: $90
Current: $8.12
Upside: +1,008.37%
Nov 15, 2024
Maintains: Buy
Price Target: $6 → $8
Current: $2.13
Upside: +275.59%
Nov 14, 2024
Maintains: Buy
Price Target: $13
Current: $0.33
Upside: +3,848.97%
Nov 7, 2024
Maintains: Buy
Price Target: $148 → $150
Current: $36.27
Upside: +313.56%
Oct 30, 2024
Maintains: Hold
Price Target: $93 → $84
Current: $58.86
Upside: +42.71%
Jan 21, 2020
Downgrades: Neutral
Price Target: n/a
Current: $96.91
Upside: -
Jul 23, 2019
Upgrades: Overweight
Price Target: $120 → $240
Current: $6.02
Upside: +3,890.02%